DGANTA Trademark

Trademark Overview


On Wednesday, September 19, 2012, a trademark application was filed for DGANTA with the United States Patent and Trademark Office. The USPTO has given the DGANTA trademark a serial number of 85732596. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 20, 2016. This trademark is owned by Novartis AG. The DGANTA trademark is filed in the Pharmaceutical Products category with the following description:

(Based on Intent to Use) Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use ...
dganta

General Information


Serial Number85732596
Word MarkDGANTA
Filing DateWednesday, September 19, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 20, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 19, 2013

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and Services(Based on Intent to Use) Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in dermatology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, anti-infectives; (Based on 44(d) Priority Application) Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in dermatology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, anti-infectives
Translation of Words in MarkThe wording "DGANTA" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, September 22, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasel
CH

Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasel
CH

Trademark Events


Event DateEvent Description
Monday, June 20, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, June 20, 2016ABANDONMENT - NO USE STATEMENT FILED
Thursday, November 19, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 18, 2015EXTENSION 5 GRANTED
Wednesday, November 11, 2015EXTENSION 5 FILED
Wednesday, November 11, 2015TEAS EXTENSION RECEIVED
Tuesday, May 26, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, May 23, 2015EXTENSION 4 GRANTED
Tuesday, May 12, 2015EXTENSION 4 FILED
Tuesday, May 12, 2015TEAS EXTENSION RECEIVED
Friday, November 14, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 13, 2014EXTENSION 3 GRANTED
Monday, November 10, 2014EXTENSION 3 FILED
Monday, November 10, 2014TEAS EXTENSION RECEIVED
Thursday, May 15, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 14, 2014EXTENSION 2 GRANTED
Thursday, April 24, 2014EXTENSION 2 FILED
Tuesday, May 13, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, April 24, 2014TEAS EXTENSION RECEIVED
Saturday, November 9, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 7, 2013EXTENSION 1 GRANTED
Thursday, November 7, 2013EXTENSION 1 FILED
Thursday, November 7, 2013TEAS EXTENSION RECEIVED
Tuesday, May 14, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 19, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 19, 2013PUBLISHED FOR OPPOSITION
Wednesday, February 27, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 11, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, February 11, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, February 11, 2013DATA MODIFICATION COMPLETED
Monday, February 11, 2013ASSIGNED TO LIE
Thursday, January 31, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 30, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 30, 2013TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, January 16, 2013NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, January 16, 2013LETTER OF SUSPENSION E-MAILED
Wednesday, January 16, 2013SUSPENSION LETTER WRITTEN
Wednesday, January 16, 2013ASSIGNED TO EXAMINER
Saturday, September 22, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, September 22, 2012NEW APPLICATION ENTERED IN TRAM